Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:11054
Name urinary bladder cancer
Definition An urinary system cancer that results_in malignant growth located_in the urinary bladder.
Source DiseaseOntology.org
Alt Ids DOID:5428
Path disease disease of cellular proliferation cancer organ system cancer urinary system cancer urinary bladder cancer

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
FGFR3 Y375C Ponatinib urinary bladder cancer sensitive detail...
FGFR3 Y375C Dovitinib urinary bladder cancer sensitive detail...
FGFR3 Y375C Cediranib urinary bladder cancer resistant detail...
FGFR3 Y375C Nintedanib urinary bladder cancer resistant detail...
FGFR3 Y375C Brivanib urinary bladder cancer no benefit detail...
FGFR3 S249C Ponatinib urinary bladder cancer sensitive detail...
FGFR3 S249C Dovitinib urinary bladder cancer sensitive detail...
FGFR3 S249C Cediranib urinary bladder cancer sensitive detail...
FGFR3 S249C Nintedanib urinary bladder cancer resistant detail...
FGFR3 S249C Brivanib urinary bladder cancer no benefit detail...
FGFR3 wild-type Ponatinib urinary bladder cancer resistant detail...
FGFR3 act mut S-49076 urinary bladder cancer predicted - sensitive detail...
FGFR3 over exp SU5402 urinary bladder cancer sensitive detail...
FGFR3 S249C Debio 1347 urinary bladder cancer sensitive detail...
FGFR3 S249C ASP5878 urinary bladder cancer sensitive detail...
HRAS mutant Metformin urinary bladder cancer sensitive detail...
PTEN del Metformin urinary bladder cancer sensitive detail...
FGFR3 mut FGFR3 over exp Dovitinib urinary bladder cancer sensitive detail...
FGFR3 over exp Dovitinib urinary bladder cancer sensitive detail...
FGFR3 over exp Infigratinib urinary bladder cancer sensitive detail...
FGFR3 over exp Dactolisib + Sorafenib urinary bladder cancer sensitive detail...
PIK3CA H1047R Dactolisib urinary bladder cancer sensitive detail...
FGFR3 mutant AZD4547 urinary bladder cancer sensitive detail...
FGFR3 fusion AZD4547 urinary bladder cancer sensitive detail...
HRAS G12V Binimetinib + Everolimus urinary bladder cancer sensitive detail...
HRAS G12V Everolimus + Selumetinib urinary bladder cancer sensitive detail...
MDM2 amp Atezolizumab urinary bladder cancer no benefit detail...
PIK3CA E545K Pictilisib urinary bladder cancer sensitive detail...
PTEN N48I Pictilisib urinary bladder cancer decreased response detail...
PIK3CA P124L PTEN del Pictilisib urinary bladder cancer decreased response detail...
PIK3CA H1047R Pictilisib urinary bladder cancer sensitive detail...
PIK3CA D549Y Pictilisib urinary bladder cancer decreased response detail...
PIK3CA E545K Cisplatin + Pictilisib urinary bladder cancer sensitive detail...
PIK3CA H1047R Cisplatin + Pictilisib urinary bladder cancer sensitive detail...
PIK3CA E545K Gemcitabine + Pictilisib urinary bladder cancer sensitive detail...
PIK3CA amp Gemcitabine + Pictilisib urinary bladder cancer sensitive detail...
PIK3CA E545K Pictilisib + Sorafenib urinary bladder cancer sensitive detail...
FGFR3 K652E Derazantinib urinary bladder cancer sensitive detail...
FGFR3 S249C Cisplatin + Ipatasertib urinary bladder cancer predicted - sensitive detail...
FGFR3 S249C Cisplatin + LY294002 urinary bladder cancer predicted - sensitive detail...
FGFR3 fusion Regorafenib urinary bladder cancer sensitive detail...
HRAS G12V ERAS-007 urinary bladder cancer sensitive detail...
NRAS Q61R RAF265 urinary bladder cancer sensitive detail...
HRAS G12V RAF265 urinary bladder cancer sensitive detail...
NRAS Q61L RAF265 urinary bladder cancer sensitive detail...
NRAS Q61R Trametinib urinary bladder cancer sensitive detail...
NRAS Q61R RAF265 + Trametinib urinary bladder cancer sensitive detail...
HRAS G12V RAF265 + Trametinib urinary bladder cancer sensitive detail...
NRAS Q61L RAF265 + Trametinib urinary bladder cancer sensitive detail...
NRAS Q61R LXH 254 urinary bladder cancer sensitive detail...
HRAS G12V LXH 254 urinary bladder cancer sensitive detail...
NRAS Q61R LXH 254 + Trametinib urinary bladder cancer sensitive detail...
FGFR3 K652E PD173074 urinary bladder cancer resistant detail...
FGFR3 S249C PD173074 urinary bladder cancer resistant detail...
FGFR3 S249C 3D185 urinary bladder cancer sensitive detail...
FGFR3 amp 3D185 urinary bladder cancer sensitive detail...
FGFR3 S249C TYRA-300 urinary bladder cancer predicted - sensitive detail...
ARID1A inact mut GSK126 urinary bladder cancer sensitive detail...
ARID1A inact mut CPI-1205 urinary bladder cancer sensitive detail...
ARID1A inact mut Tazemetostat urinary bladder cancer sensitive detail...
ARID1A inact mut MAK683 urinary bladder cancer sensitive detail...
ARID1A dec exp GSK126 urinary bladder cancer sensitive detail...
ARID1A dec exp CPI-1205 urinary bladder cancer sensitive detail...
ARID1A dec exp Tazemetostat urinary bladder cancer sensitive detail...
ARID1A dec exp MAK683 urinary bladder cancer sensitive detail...
ARID1A dec exp Alpelisib urinary bladder cancer sensitive detail...
ARID1A dec exp Pictilisib urinary bladder cancer sensitive detail...
ARID1A dec exp Dactolisib urinary bladder cancer sensitive detail...
ARID1A dec exp GSK126 + Pictilisib urinary bladder cancer sensitive detail...
ARID1A inact mut Pictilisib urinary bladder cancer sensitive detail...
FGFR3 K652E PIK3CA P124L Alpelisib + Nintedanib urinary bladder cancer sensitive detail...
FGFR3 K652E PIK3CA P124L Nintedanib + Pictilisib urinary bladder cancer sensitive detail...
PIK3CA E542Q PIK3CA E674Q Alpelisib + Nintedanib urinary bladder cancer sensitive detail...
PIK3CA E542Q PIK3CA E674Q Nintedanib + Pictilisib urinary bladder cancer sensitive detail...
FGFR3 R248C PIK3CA A1066V Nintedanib + Pictilisib urinary bladder cancer sensitive detail...
FGFR3 Y373C Pemigatinib urinary bladder cancer predicted - sensitive detail...
FGFR3 S249C Erdafitinib + Quisinostat urinary bladder cancer sensitive detail...
PIK3CA A1066V MK2206 urinary bladder cancer resistant detail...
PIK3CA P124L MK2206 urinary bladder cancer resistant detail...
PIK3CA E545K MK2206 urinary bladder cancer sensitive detail...
PIK3CA E545G MK2206 urinary bladder cancer sensitive detail...
PIK3CA E542K PIK3CA E674Q MK2206 urinary bladder cancer sensitive detail...
FGFR3 S249C Erdafitinib urinary bladder cancer sensitive detail...
FGFR3 Y373C Erdafitinib urinary bladder cancer sensitive detail...
FGFR3 R248C Erdafitinib urinary bladder cancer predicted - sensitive detail...
FGFR3 G370C Erdafitinib urinary bladder cancer predicted - sensitive detail...
FGFR3 S249C CPL304110 urinary bladder cancer sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT00313599 Phase I Lapatinib + Paclitaxel Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors Completed USA 0
NCT00959868 Phase I Apatorsen A Study for Treatment of Superficial Bladder Cancer Using OGX-427 Unknown status CAN 0
NCT01730118 Phase I HER2 Vaccine Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing Completed USA 0
NCT01738815 Phase I Valproic acid Impact of Valproate on Angiogenesis and Histone Deacetylation in Bladder Cancer Completed USA 0
NCT01928394 Phase Ib/II Ipilimumab + Nivolumab Cobimetinib + Ipilimumab + Nivolumab Nivolumab A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors Active, not recruiting USA | ITA | GBR | ESP | DEU | CAN 2
NCT01966445 Phase I GSK2849330 Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors Completed USA | NLD | AUS 0
NCT01968109 Phase I Nivolumab + Relatlimab Relatlimab Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors Active, not recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | AUT | AUS 5
NCT01976741 Phase I Rogaratinib Phase I Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor Completed USA | FRA | ESP | DEU 3
NCT02030067 Phase Ib/II RX-3117 Dose-Finding and Safety Study for Oral Single-Agent to Treat Advanced Malignancies Completed USA 0
NCT02043665 Phase I Coxsackievirus A21 Systemic Treatment Of Resistant Metastatic Disease Employing CVA21 and Pembrolizumab in Non-small Cell Lung Cancer and Bladder Cancer (STORM/ KEYNOTE-200) (STORM) Completed USA | GBR | AUS 0
NCT02091141 Phase II Erlotinib Alectinib Cobimetinib + Vemurafenib Pertuzumab + Trastuzumab Vismodegib Atezolizumab My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors Completed USA 0
NCT02177695 Phase II Cisplatin + Gemcitabine Aldoxorubicin + Cisplatin + Filgrastim + Methotrexate + Vinblastine S1314, Co-expression Extrapolation (COXEN) Program to Predict Chemotherapy Response in Patients With Bladder Cancer Completed USA 0
NCT02323191 Phase I Atezolizumab + Emactuzumab A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors Completed USA | FRA | ESP | BEL 0
NCT02346955 Phase I CM-24 CM-24 + Pembrolizumab Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001) Terminated USA 1
NCT02351739 Phase II Pembrolizumab Acalabrutinib Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Platinum-refractory Metastatic Bladder Cancer Completed USA 0
NCT02360618 Phase II Metformin + Simvastatin Metformin and Simvastatin Use in Bladder Cancer Unknown status CAN 0
NCT02365818 Phase II CG0070 Safety and Efficacy of CG0070 Oncolytic Virus Regimen for High Grade Non-Muscle Invasive Bladder Cancer After BCG Failure Completed USA 0
NCT02452424 Phase Ib/II Pembrolizumab + Pexidartinib A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors Terminated USA 0
NCT02528357 Phase I GSK3174998 Pembrolizumab GSK3174998 Alone or With Pembrolizumab in Subjects With Advanced Solid Tumors Completed USA | NLD | FRA | CAN 0
NCT02529553 Phase I LY3076226 A Study of LY3076226 in Participants With Advanced or Metastatic Cancer Completed USA | CAN 0
NCT02543645 Phase Ib/II Atezolizumab + Varlilumab A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer Terminated USA 0
NCT02554812 Phase Ib/II Avelumab + PF-04518600 Avelumab + PD 0360324 Avelumab + Utomilumab Avelumab + PF-04518600 + Utomilumab A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley) Terminated USA | GBR | FRA | CAN | AUS 3
NCT02605863 Phase II Enzalutamide Enzalutamide for Bladder Cancer Chemoprevention Terminated USA 0
NCT02643303 Phase Ib/II Durvalumab + Poly ICLC Tremelimumab A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers Completed USA 0
NCT02646319 Phase I Nab-rapamycin Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations Completed USA 0
NCT02675829 Phase II Ado-trastuzumab emtansine Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers Recruiting USA 0
NCT02753309 Phase 0 Sirolimus A Study of Rapamycin Combined With Intravesical BCG in Patients With Non-muscle Invasive Bladder Cancer Completed USA 0
NCT02808143 Phase I BCG solution + Pembrolizumab Pembrolizumab and BCG Solution in Treating Patients With Recurrent Non-Muscle-Invasive Bladder Cancer Active, not recruiting USA 0
NCT02880371 Phase Ib/II ARRY-382 + Pembrolizumab A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors Terminated USA 0
NCT02952248 Phase I Ezabenlimab A Trial to Find and Investigate a Safe Dose of a New Substance (BI 754091) for Patients With Solid Tumours Completed USA | GBR | CAN 0
NCT03023319 Phase I Bosutinib + Pemetrexed Disodium Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors Completed USA 0
NCT03224182 Phase III Apaziquone A Study of Intravesical Qapzola (Apaziquone) as a Surgical Adjuvant in Patients Undergoing TURBT Terminated USA 0
NCT03294304 Phase II Cisplatin + Gemcitabine + Nivolumab Nivolumab, Gemcitabine, and Cisplatin in Treatment of Bladder Cancer (MIBC) Undergoing Cystectomy Completed USA 0
NCT03298958 Phase III Sirolimus Secondary Prevention Trial of Rapamycin in Patients With Resected Non-muscle Invasive Bladder Cancer Withdrawn USA 0
NCT03319745 Phase II Pembrolizumab A Window of Opportunity Study of Pembrolizumab in Patients With Bladder Cancer Undergoing Radical Cystectomy Completed USA 0
NCT03330561 Phase I PRS-343 PRS-343 in HER2-Positive Solid Tumors Completed USA 0
NCT03333616 Phase II Ipilimumab + Nivolumab Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors Active, not recruiting USA 0
NCT03454451 Phase I CPI-006 CPI-006 + Pembrolizumab CPI-006 + CPI-444 CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers Completed USA | AUS 0
NCT03519256 Phase II Linrodostat + Nivolumab Nivolumab BCG solution + Nivolumab BCG solution + Linrodostat + Nivolumab A Study of Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without Bacillus Calumette-Guerin (BCG) in BCG Unresponsive Bladder Cancer That Has Not Invaded Into the Muscle Wall of the Bladder (CheckMate 9UT) Terminated USA | NLD | ITA | GBR | FRA | ESP | CAN | AUS 7
NCT03568539 Phase Ib/II Sintilimab IBI308 in Subjects With Advanced/Metastatic Solid Malignancies Completed USA 0
NCT03596372 Phase I BAY1834942 Study of BAY1834942 in Patients With Solid Tumors Completed USA | CAN 1
NCT03628677 Phase I AB154 AB154 + Zimberelimab A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies Active, not recruiting USA | AUS 0
NCT03629756 Phase I Etrumadenant + Zimberelimab A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies Completed USA | AUS 0
NCT03637803 Phase I MRx0518 + Pembrolizumab MRx0518 and Pembrolizumab Combination Study Terminated USA 0
NCT03661320 Phase III Cisplatin + Gemcitabine + Nivolumab Cisplatin + Gemcitabine Cisplatin + Gemcitabine + Linrodostat + Nivolumab A Study of Chemo Only Versus Chemo Plus Nivo With or Without BMS-986205, Followed by Post- Surgery Therapy With Nivo or Nivo and BMS-986205 in Patients With MIBC Active, not recruiting USA | NZL | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 16
NCT03762161 Phase II Trifluridine-tipiracil hydrochloride A Phase II Study of Lonsurf (TAS-102) in Metastatic Platinum and Checkpoint Inhibitor-resistant Bladder Cancer Unknown status USA 0
NCT03767348 Phase Ib/II Nivolumab + RP1 RP1 Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE) Recruiting USA | GBR | FRA | ESP | DEU 0
NCT03775850 Phase Ib/II EDP1503 EDP1503 + Pembrolizumab A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors Completed USA | CAN 0
NCT03792724 Phase Ib/II Nivolumab + Urelumab Phase I-II Study of Intratumoral Urelumab Combined With Nivolumab in Patients With Solid Tumors (INTRUST) Unknown status ESP 0
NCT03816345 Phase I Nivolumab Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer Recruiting USA | CAN 0
NCT03872947 Phase I Pembrolizumab + TRK-950 Carboplatin + Gemcitabine + TRK-950 Imiquimod + TRK-950 Paclitaxel + Ramucirumab + TRK-950 Nivolumab + TRK-950 Cisplatin + Gemcitabine + TRK-950 Fluorouracil + Irinotecan + Leucovorin + TRK-950 A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors Recruiting USA | FRA 0
NCT03892642 Phase Ib/II Avelumab + BCG solution Avelumab Plus Bacille Calmette-Guerin (BCG) in Patients With Non-muscle Invasive Bladder Cancer Completed USA 0
NCT03915678 Phase II Atezolizumab + BDB001 Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors (AGADIR) Recruiting FRA 0
NCT04068896 Phase I NGM120 Study of NGM120 in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy Active, not recruiting USA 0
NCT04112498 Phase I Nivolumab + Relatlimab + rHuPH20 A Phase 1, Bioavailability Study of Relatlimab in Combination With Nivolumab Completed USA 0
NCT04134312 Phase I MVA-BN-Brachyury A Phase 1 Open Label Trial of Intravenous Administration of MVA-BN-Brachyury Vaccine in Patients With Advanced Cancer Completed USA 0
NCT04145622 Phase Ib/II Ifinatamab deruxtecan Study of DS-7300a in Participants With Advanced Solid Malignant Tumors Recruiting USA 1
NCT04152499 Phase Ib/II SKB264 Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (A264) Recruiting USA 1
NCT04179162 Phase Ib/II BCG solution + Gemcitabine Bacillus Calmette-Guerin (BCG) and Gemcitabine in People With High-Grade Non-Muscle Invasive Bladder Cancer That Came Back After BCG Treatment Recruiting USA 0
NCT04209114 Phase III Nivolumab + NKTR-214 Nivolumab A Study of Nivolumab Plus NKTR-214 vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That Has Invaded the Muscle Wall of the Bladder and Who Cannot Get Cisplatin, a Type of Medicine Given to Treat Bladder Cancer. Completed USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 9
NCT04241185 Phase III Pembrolizumab Cisplatin Mitomycin C Gemcitabine Fluorouracil Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992) Recruiting USA | NLD | ITA | GBR | FRA | ESP | AUS 18
NCT04243499 Phase I ICT01 First-in-Human Study of ICT01 in Patients With Advanced Cancer (EVICTION) Recruiting USA | GBR | FRA | ESP | DEU | BEL 0
NCT04250597 Phase I GNX102 Study of GNX102 in Patients With Advanced Solid Tumors Terminated USA 1
NCT04260802 Phase Ib/II OC-001 + unspecified PD-L1 antibody OC-001 + unspecified PD-1 antibody OC-001 A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers Recruiting CAN 0
NCT04344795 Phase I TPST-1495 Pembrolizumab + TPST-1495 Phase 1a/1b Study of TPST-1495 Alone and With Pembrolizumab in Subjects With Solid Tumors Recruiting USA 0
NCT04383743 Phase Ib/II Cisplatin + Doxorubicin + Methotrexate + Pegfilgrastim + Pembrolizumab + Vinblastine Pembrolizumab and Combination Chemotherapy Before Surgery for the Treatment of Muscle-Invasive Bladder Cancer Recruiting USA 0
NCT04387461 Phase II CG0070 + Dodecyl Maltoside + Pembrolizumab Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin (Core-001) Active, not recruiting USA 1
NCT04389632 Phase I SGN-B6A A Study of SGN-B6A in Advanced Solid Tumors Recruiting USA | GBR | FRA | ESP 1
NCT04424641 Phase Ib/II GEN1044 A Study on the Safety of GEN1044 (DuoBody-CD3x5T4) in Subjects With Malignant Solid Tumors Terminated USA | ESP 2
NCT04430842 Phase I QBS10072S Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S Completed AUS 0
NCT04452591 Phase III CG0070 + Dodecyl Maltoside Study of CG0070 Given in Patients With Non-Muscular Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin (BOND-003) Recruiting USA | AUS 3
NCT04482309 Phase II Trastuzumab deruxtecan A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors (DPT02) Active, not recruiting USA | NLD | ITA | GBR | ESP | CAN | BEL | AUS 7
NCT04525131 Phase II CPX-POM Safety, Dose Tolerance, Pharmacokinetics, Pharmacodynamics of CPX-POM in Patients With Newly Diagnosed or Recurrent Bladder Tumors Completed USA 0
NCT04580485 Phase I INCB106385 + Retifanlimab INCB106385 INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors Completed USA | ITA | GBR | FRA | ESP | BEL 0
NCT04690699 Phase Ib/II PVSRIPO + unspecified PD-1 antibody LUMINOS-103: A Basket Trial Evaluating the Safety and Efficacy of PVSRIPO and PVSRIPO in Combination With Anti-PD-1/L1 Checkpoint Inhibitors in Patients With Advanced Solid Tumors Active, not recruiting USA 0
NCT04713891 Phase I KF-0210 Atezolizumab + KF-0210 A Study of KF-0210 in Advanced Solid Tumors Patients Unknown status AUS 0
NCT04836195 Phase I PCLX-001 Phase I Trial of PCLX-001 in R/R Advanced Solid Malignancies and B-cell Lymphoma Recruiting CAN 0
NCT04851834 Phase Ib/II Cisplatin + NTX-301 NTX-301 NTX-301 + Temozolomide Carboplatin + NTX-301 NTX-301 Monotherapy in Advanced Solid Tumours and in Combination With Platinum-based Chemotherapy in Advanced Ovarian & Bladder Cancer and in Combination With Temozolomide in High-grade Glioma Terminated AUS 0
NCT04902040 Phase Ib/II Atezolizumab + Avelumab + Durvalumab + Nivolumab + Pembrolizumab + Plinabulin Atezolizumab + Avelumab + Durvalumab + Nivolumab + Pembrolizumab Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies Recruiting USA 0
NCT04917809 Phase II Erdafitinib A Study of Oral Erdafitinib in People With Recurrent Non-Invasive Bladder Cancer Recruiting USA 0
NCT04969835 Phase I AVA6000 A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours Recruiting USA | GBR 0
NCT05057013 Phase Ib/II HMBD-001 HMBD-001 in Advanced HER3 Positive Solid Tumours Recruiting GBR 0
NCT05086692 Phase Ib/II MDNA11 + Pembrolizumab A Beta-only IL-2 ImmunoTherapY Study (ABILITY-1) Recruiting USA | CAN | AUS 1
NCT05120622 Phase Ib/II Durvalumab + Tremelimumab Trial of Local Cystoscopic Injection of Tremelimumab Plus Systemic Durvalumab for High Risk Non-Muscle Invasive Bladder Cancer (Rideau) Withdrawn CAN 0
NCT05126472 Phase I 2141 V-11 Study of 2141-V11 in People With Non-muscle Invasive Bladder Cancer That Did Not Respond to Standard Treatment Recruiting USA 0
NCT05144698 Phase II RAPA-201 RAPA-201 Therapy of Solid Tumors Recruiting USA 0
NCT05259319 Phase I Atezolizumab + Tiragolumab Study Evaluating the Safety and the Efficacy of Combination of Atezolizumab, Tiragolumab and and Stereotactic Body Radiation Therapy in Patients With Oligometastatic Multiorgan (IMMUNOs-SBRT) (IMMUNOs-SBRT) Recruiting FRA 0
NCT05298592 Phase I BMS-986406 + Nivolumab BMS-986406 A Study of BMS-986406 as Monotherapy and Combination Therapies in Participants With Advanced Tumors Recruiting USA | ESP | BEL 3
NCT05358379 Phase Ib/II CYC140 A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymphoma Recruiting USA | ESP 1
NCT05420636 Phase II ORY-1001 + Paclitaxel Iadademstat in Combination With Paclitaxel in Relapsed/Refractory SCLC and Extrapulmonary High Grade NET Recruiting USA 0
NCT05512377 Phase II BI 907828 Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder Recruiting USA | GBR | FRA | ESP | DEU | BEL | AUT | AUS 6
NCT05581589 Phase II Sacituzumab govitecan-hziy Sacituzumab Govitecan Before Radical Cystectomy for the Treatment of Non-Urothelial Muscle Invasive Bladder Cancer Recruiting USA 0
NCT05655598 Phase I Palbociclib + Pimitespib TAS-116 Plus Palbociclib in Breast and Rb-null Cancer Recruiting USA 0
NCT05704985 Phase I DK210 DK210 + Nivolumab Paclitaxel DK210 + Pembrolizumab Oxaliplatin Capecitabine Fluorouracil Carboplatin Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors Recruiting USA 0
NCT05718557 Phase I PYX-106 Study of PYX-106 in Solid Tumors Recruiting USA | ESP | BEL 0
NCT05836324 Phase I INCA33890 A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors Recruiting USA | ITA | GBR | FRA | ESP 2
NCT05891171 Phase I AB598 + Carboplatin + Pemetrexed Disodium + Zimberelimab AB598 AB598 + Fluorouracil + Leucovorin + Oxaliplatin + Zimberelimab Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers (ARC-25) Recruiting USA 0
NCT05944237 Phase Ib/II Atezolizumab + HTL0039732 HTL0039732 HTL0039732 in Participants With Advanced Solid Tumours Recruiting GBR 0
NCT05947474 Phase I ORB-011 ORB-011 In Patients With Advanced Solid Tumors (ORB) Recruiting USA 0
NCT05951179 Phase Ib/II TARA-002 Dose Expansion, Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer (ADVANCED-2) Recruiting USA 1
NCT06014502 Phase I IMGS-001 Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors Recruiting USA 0
NCT06171789 Phase Ib/II PRO1107 PRO1107 in Patients With Advanced Solid Tumors Recruiting USA 0
NCT06237920 Phase II Nivolumab Nivolumab + Relatlimab Stage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without Relatlimab (TURANDORELA) Recruiting NLD 0
NCT06242470 Phase I MGC026 A Study of MGC026 in Participants With Advanced Solid Tumors Recruiting USA 0
NCT06279130 Phase II Balstilimab Balstilimab + Botensilimab Pan-tumor Neoadjuvant Basket Study of Immune Check-point Inhibition and Novel Immuno-oncology Combinations (NEOASIS) Recruiting NLD 0